NFAT-Specific Inhibition by dNP2-VIVIT Ameliorates Autoimmune Encephalomyelitis by Regulation of Th1 and Th17

Hong-Gyun Lee,1,2,4 Li-Kyung Kim,1,2,4 and Je-Min Choi1,2,3

Nuclear factor of activated T cells (NFATs) is an important transcription factor for T cell activation and proliferation. Recent studies have highlighted the role of NFATs in regulating the differentiation of effector CD4 T helper (Th) subsets including Th1 and Th17 cells. Because controlling the effector T cell function is important for the treatment of autoimmune diseases, regulation of NFAT functions in T cells would be an important strategy to control the pathogenesis of autoimmune diseases. Here, we demonstrated that an NFAT inhibitory peptide, VIVIT conjugated to dNP2 (dNP2-VIVIT), a blood-brain barrier-permeable peptide, ameliorated experimental autoimmune encephalomyelitis (EAE) by inhibiting Th1 and Th17 cells, but not regulatory T (Treg) cells. dNP2-VIVIT negatively regulated spinal cord-infiltrating interleukin-17A (IL-17A) and interferon (IFN)-γ-producing CD4+ T cells without affecting the number of Foxp3+ CD4+ Treg cells, whereas dNP2-VEET or 11R-VIVIT could not significantly inhibit EAE. In comparison with cyclosporin A (CsA), dNP2-VIVIT selectively inhibited Th1 and Th17 differentiation, whereas CsA inhibited the differentiation of all T cell subsets including that of Th2 and Treg cells. Collectively, this study demonstrated the role of dNP2-VIVIT as a novel agent for the treatment of autoimmune diseases such as multiple sclerosis by regulating the functions of Th1 and Th17 cells.

INTRODUCTION

The nuclear factor of activated T cells (NFATs) proteins are important transcription factors involved in the regulation of T cell receptor (TCR) signaling and functions.1–3 To date, five NFAT family members have been identified that share a highly conserved DNA-binding domain, NFAT1 (NFATc2 or NFATp), NFAT2 (NFATc1 or NFATc2), NFAT3 (NFATc4), NFAT4 (NFATc3 or NFATx), and NFAT5 (TonEBP or OREBP).4 Whereas four of these proteins are regulated by calcium signaling, NFAT5 is calcium independent and is activated under conditions of osmotic stress. Binding of the TCR to the antigen increases intracellular calcium levels, thereby activating serine/threonine phosphatase calcineurin.5–7 Activated calcineurin binds and dephosphorylates NFATs, leading to its nuclear translocation and induction of inflammatory cytokine gene expression.6,8 Recently, the NFATs have been re-highlighted to play important roles in regulating the expression of lineage-specific transcription factors and signature cytokines of CD4 T helper subsets including T helper 1 (Th1) and Th17 cells.9–12 NFAT1/NFAT4 and NFAT1/NFAT2 deficiency has been shown to impair IFN-γ production.13–15 NFAT1 has been reported to directly bind to the IFN-γ promoter,11,16 and loss of NFAT1 was found to increase the resistance to the induction of EAE and significantly decrease the levels of IFN-γ production by CNS-infiltrating CD4+ T cells.17 Likewise, in Th17 cells, NFAT1 and NFAT2 proteins directly bound to the interleukin-17 (IL-17) promoter.18,19 NFAT1-deficient T cells produced IL-17A along with IL-4 and IL-10, which are not pathogenic.17 Loss of NFAT2 in CD4+ T cells led to reduced IL-17A, IL-17F, IL-21, and RORγt expression, and NFAT1- and NFAT2-deficient (double-knockout [DKO]) mice were resistant to the induction of EAE. Moreover, NFAT1 deficiency exerted a protective effect against experimental colitis through reduced production of IL-6 and IL-17 by mucosal T lymphocytes.20 Considering the important role of NFAT signaling in T cell responses, the NFATs has been targeted for the treatment of autoimmune diseases for decades.21–24 The most commonly used drugs for targeting NFATs are calcineurin inhibitors, CsA and FK506. Upon entering the cells, these inhibitors form a complex with immunophilins, cyclophilins, and FK-binding protein 12 (FKBP12), respectively.25–27 This complex directly binds to calcineurin and inhibits its phosphatase activity, thereby inhibiting NFAT dephosphorylation.28 Although calcineurin inhibitors effectively regulate T cell responses and are widely used to control the pathogenicity of autoimmune diseases and graft rejection, they have been reported to have serious drawbacks, including neurotoxicity, nephrotoxicity, and regulatory T (Treg) cell count reduction.29–32

\[\text{Received 17 September 2019; accepted 16 October 2019; https://doi.org/10.1016/j.omtm.2019.10.006.}\]

\[\text{These authors contributed equally to this work.}\]

\[\text{Correspondence: Je-Min Choi, Department of Life Science, College of Natural Sciences, Hanyang University, 222 Wangsimni-ro, Seongdong-gu, Seoul 04763, Republic of Korea.}\]

\[\text{E-mail: jeminchoi@hanyang.ac.kr}\]
To overcome the limitations associated with calcineurin inhibitors, we developed the VIVIT peptide based on the common calcineurin-NFAT binding motif PxIxIT, which selectively regulates NFAT transcription factor. The VIVIT peptide effectively inhibited NFAT-dependent gene expression without affecting the calcineurin phosphatase activity.

Here, we utilized a cell-permeable peptide, dNP2, which is a promising blood-brain-barrier-permeable peptide that can deliver cargoes into primary T cells and to the cells of the brain and spinal cord.

We synthesized VIVIT conjugated with dNP2 (dNP2-VIVIT), which could strongly ameliorate EAE severity and demyelination. dNP2-VIVIT inhibited CNS invasion of CD4+ T cells and significantly reduced IL-17A and IFN-γ production. EAE inhibition by the VIVIT peptide was more significant in conjugation with dNP2, but not with 11R. In comparison with CsA, dNP2-VIVIT specifically inhibited Th1 and Th17 cell differentiation, whereas CsA inhibited all T cell subsets including the differentiation of Treg and Th2 cells. Taken together, our findings demonstrate that a blood-brain barrier-permeable peptide conjugated with VIVIT (dNP2-VIVIT) could be an effective immunomodulatory agent for treating multiple sclerosis through specific inhibition of NFATs.

RESULTS

The Synthetic Peptide dNP2-VIVIT Ameliorates Experimental Autoimmune Encephalomyelitis

To examine the inhibitory effects of NFAT function in autoimmune encephalomyelitis, we synthesized a 40-amino-acid-long, highly pure VIVIT peptide conjugated with dNP2 (dNP2-VIVIT) (97% purity when purified by high-pressure liquid chromatography [HPLC] analysis) (Figures 1A–1C). We also constructed a negative control peptide conjugate (dNP2-VEET), which has a non-functional mutation sequence of VIVIT. In order to determine the function of NFAT-specific inhibition by dNP2-VIVIT, we used EAE, a Th1/Th17-mediated autoimmune neuroinflammation mouse model of multiple sclerosis. Eight-week-old female C57BL/6 mice were immunized with the MOG35–55 peptide on day 0 and were treated with pertussis toxin on days 0 and 2. dNP2-VIVIT or dNP2-VEET (100 μg) were intraperitoneally administered every other day starting from day 7. The mice were monitored daily for the clinical score and were sacrificed on day 17 (Figure 2A). dNP2-VIVIT treatment significantly delayed EAE onset and disease progression (Figure 2B). The percentage of EAE incidence was also reduced remarkably by dNP2-VIVIT, whereas no effects were observed in dNP2-VEET-treated or PBS control mice (Figure 2C). Spinal cord tissue histology revealed reduced demyelination and cellular infiltration upon dNP2-VIVIT treatment in comparison with the control groups (Figures 2D and 2E). On examining the cellular characteristics of spinal cord cells by single-cell isolation, we found that the reduction in the total number of CNS-infiltrating cells observed upon dNP2-VIVIT treatment correlated with the reduction in the number of CD4+ T cells (Figure 2F). Importantly, dNP2-VIVIT treatment significantly decreased both the proportion and number of IL-17A- and/or IFN-γ-producing CD4+ T cells in the spinal cord (Figures 2G and 2H). However, the proportion of CD4+Foxp3+ T cells in the spinal cord was not significantly different (Figures 2I and 2J), suggesting that dNP2-VIVIT specifically inhibited encephalitogetic T cells. Taken together, these data suggest that dNP2-VIVIT could regulate pathogenic T cells and ameliorate disease progression during autoimmune neuroinflammation.

dNP2-VIVIT, but Not CsA, Specifically Regulates Th1 and Th17 Differentiation In Vitro

Because EAE progression is mainly caused by myelin antigen-specific Th1 and Th17 cells or because of the imbalance between effector cells and Treg cells, we further investigated dNP2-VIVIT function in CD4+ T cell differentiation in vitro. FACS-sorted naive (CD4+CD25−CD62LhighCD44low) T cells were differentiated into Th1, Th2, Th17, and iTreg cells, and their effector cytokine responses were analyzed by flow cytometry and ELISA. dNP2-VIVIT regulated Th1 (Figures 3A–3C) and Th17 differentiation (Figures 3D–3F) by...
Figure 2. NFAT Inhibitory Peptide dNP2-VIVIT Ameliorated Experimental Autoimmune Encephalomyelitis (EAE)

EAE was induced in 8-week-old female C57BL/6 mice by immunization with MOG in complete Freund’s adjuvant. (A) The mice were treated intraperitoneally with PBS or 100 μg dNP2-VVIT or dNP2-VEET on day 7 after immunization, and were subsequently treated every other day. Clinical scores (B) and incidence (C) were monitored daily (n = 10 per group). Data are presented as the mean ± SEM of two independent experiments. (D) Spinal cord tissues were harvested and observed after Luxol fast blue (LFB) and

(legend continued on next page)
significantly inhibiting effector cytokine (IFN-γ and IL-17A) production. However, dNP2-VIVIT failed to inhibit Th2 (Figures 3G–3I) or iTreg (Figures 3J and 3K) differentiation. Importantly, the calcineurin inhibitor, CsA, potently suppressed all T cell subsets (Th1, Th2, Th17, and iTreg) without showing significant toxicity (Figure S1), suggesting that the specificity of T cell differentiation by VIVIT was different from that of CsA. Collectively, these results demonstrate that NFAT inhibition by dNP2-VIVIT could specifically regulate the differentiation of Th1 and Th17 cells. This could explain the possible mechanism and advantage of dNP2-VIVIT over CsA with respect to its regulatory function in EAE pathogenesis.

dNP2 Is Required for Efficient VIVIT Internalization into T Cells and Alleviating EAE

Because NFATs is critical for T cell activation, NFAT inhibition has already been attempted by using a poly arginine of 11R (11R-VIVIT) VIVIT peptide. However, no studies have been carried out to assess its ability to control T cell-mediated autoimmune disease, except for one report that demonstrated increased success rate of allogeneic islet transplantation upon treatment with 11R-VIVIT.\(^{36}\) Based on our previous findings, we hypothesized that the dnp2 peptide is critical for the efficient delivery of VIVIT peptide into T cells, thereby allowing inhibition of autoimmune diseases like EAE. By utilizing identical EAE designs, the in vivo efficacy of dNP2-VIVIT and 11R-VIVIT was comparatively analyzed. Upon treating mice with an equivalent amount of VIVIT peptides (100 µg), 11R-VIVIT could not control EAE onset or progression, whereas a high dose (400 µg) of this peptide showed partial effects on controlling EAE severity (Figures 4A and 4B). Remarkably, the EAE clinical scores of the mice treated with dNP2-VIVIT were significantly lower than those of that treated with 11R-VIVIT (100 µg, 400 µg) or PBS. The spinal cord-infiltrating IFN-γ- and IL-17A-producing cell numbers correlated with the clinical score of EAE disease. dNP2-VIVIT potently inhibited Th1 or Th17 cells in the CNS compared with 11R-VIVIT (100 µg), both in their proportion (Figure 4C) and the number (Figure 4D), without affecting the proportion of Treg cells (Figure 4E). Four times dose (400 µg) treatment of 11R-VIVIT showed partial reduction in the number of encephalitogenic T cells in the CNS, suggesting that dNP2-VIVIT is a more effective peptide than 11R with respect to regulating T cell effector functions and EAE pathogenesis.

dNP2, but Not 11R, Delivers Cargo Proteins to CNS Tissues

Based on our findings that dNP2-VIVIT significantly ameliorated EAE pathogenicity, whereas 11R VIVIT did not, we hypothesized that the therapeutic effect of VIVIT peptide mediated by dNP2 would be due to the efficient cargo delivery into the CNS, by bypassing the blood-brain barrier. To visualize the intracellular protein delivery by dNP2 or 11R in vivo, we constructed plasmids expressing dTomato with or without the cell-penetrating peptides dNP2 and 11R (Figure 5A), and purified the resultant proteins as previously described (Figure 5B).\(^{37}\) The intracellular transduction efficiency of these purified proteins was examined by incubation with isolated naive (CD4+CD25−CD62LhighCD44low) T cells that are generally known to be hard to transfect. Flow cytometric analysis demonstrated higher transduction efficiency of dNP2-dTomato into naive CD4+ T cells relative to 11R-dTomato (Figure 5C), in a concentration-dependent manner (Figure 5D). Furthermore, we analyzed the brain and spinal cord tissue localization of dNP2-dTomato, 11R-dTomato, and dTomato proteins after 2 h of intravenous injection. Sectioned brain and spinal cord tissues were examined under a fluorescent microscope. dNP2-dTomato signal was significantly detected in the brain and spinal cord tissues, whereas 11R-dTomato and dTomato signal was barely observed (Figure 5E), suggesting that the blood-brain barrier (BBB) penetrability of dNP2 is significantly higher than that of the other controls. Therefore, we suggest that the delivery of VIVIT peptide conjugated with CNS-permeable peptide dNP2 would have an advantage with respect to inducing efficient NFAT-specific inhibition in CNS-infiltrating T cells, which might presumably allow the dNP2-VIVIT peptide to control in vivo physiology during EAE progression.

DISCUSSION

In this study, we present the successful application of the NFAT inhibitory peptide, VIVIT, for in vivo modulation of encephalitogenic T cell functions and CNS autoimmune neuroinflammation. A potent cell-penetrating peptide, dNP2, which enables efficient cargo delivery in CNS tissues allowed VIVIT to selectively regulate the differentiation of Th1 and Th17 cells and to strongly reduce EAE severity and demyelination.

Over the last decade, NFAT transcription factor has been targeted for the treatment of autoimmune diseases because of its critical role in calcium signaling initiated by TCR engagement. Considering the important role of T cells in autoimmune disease, modulation of calcium signaling-mediated T cell regulation was targeted by developing calcineurin inhibitors such as cyclosporine A (CsA) and tacrolimus (FK506). CsA and tacrolimus are used in autoimmune diseases including rheumatoid arthritis, membranous nephropathy, and systemic lupus erythematosus.\(^{21,23,39,40}\) Previous studies revealed that CsA treatment suppressed the effector function of Th17 cells in patients with rheumatoid arthritis and Sjögren’s syndrome.\(^{41,42}\) Moreover, a recent study reported that tacrolimus can be effective for maintaining remission in patients with rheumatoid arthritis.\(^{43}\) Although these chemical inhibitors have
been used in clinical applications against human autoimmune diseases, they have serious disadvantages such as neurotoxicity and nephrotoxicity. Calcineurin inhibitors directly suppress the calcineurin phosphatase activity, and thus they broadly affect all of the signaling pathways associated with calcineurin. Calcineurin has been reported to be highly expressed in brain tissues and is known to modulate the Ca\(^{2+}\) influx by binding to the inositol triphosphate (IP\(_3\)) and ryanodine receptors. Calcineurin also affects the activity of gamma aminobutyric acid (GABA) and N-methyl-D-aspartate (NMDA) receptors, thereby regulating neurotransmitter recycling and exocytosis. Treatment with calcineurin inhibitors upregulated the expression of transforming growth factor \(\beta\) (TGF-\(\beta\)) and endothelin, which induced nephrotic effects such as endothelial dysfunction, impaired glomerular filtration, systemic hypertension, and tubular fibrosis. Moreover, recent studies have reported that calcineurin inhibitors negatively affected T regulatory cell (T reg) cell proliferation and function, which have a pivotal role in immune tolerance. To overcome the limitations associated with the currently used calcineurin inhibitors, we developed the VIVIT peptide. The VIVIT peptide selectively regulates NFATs through interaction with the conserved calcineurin NFAT binding motif PxlxlT without affecting calcineurin phosphatase activity. For efficient in vivo therapeutic application, previous studies utilized various cell-permeable forms of the VIVIT peptide. One study reported

Figure 3. NFAT-Specific Inhibition by dNP2-VIVIT Suppresses Th1 and Th17 Differentiation

Naive (CD4\(^{+}\)CD25\(^{-}\)CD62L\(^{hi}\)CD44\(^{lo}\)) T cells were differentiated into Th1 (A–C), Th2 (D–F), Th17 (G–I), and iTreg (J and K) skewing conditions in the presence of anti-CD3/CD28 stimulation for 5 days. Cells were incubated with 1 \(\mu\)M dNP2-VEET, dNP2-VIVIT, and 20 ng/mL CsA. The frequencies and concentrations of IFN-\(\gamma\) (A–C) and IL-17A (D–F) in the supernatants were analyzed by flow cytometry and ELISA. (G–I) The frequencies of IL-4 and IL-13 were analyzed by flow cytometry. (J and K) Foxp3-expressing cells were analyzed. Data are presented as mean ± SEM of three (n = 3) independent experiments (A–F, J, and K) or are representative of four (n = 4) independent experiments (G–I); statistical analysis by two-tailed Student’s t test. *\(p < 0.05\), **\(p < 0.01\), ***\(p < 0.001\). NS, not significant.
that the cell-penetrating peptide (CPP) 11 arginine-conjugated VIVIT successfully increased transplant survival in islet transplanted mice. Another cell-penetrating peptide known as Sim-2-conjugated VIVIT inhibited IL-2 production in an ovalbumin (OVA)-induced asthma model. However, none of the VIVIT conjugates studied so far have reached clinical trials, implying that the existing CPP-based VIVIT peptides may have lower delivery efficiency in hard-to-transfect cells like human primary cells or T cells. Moreover, considering the important role of NFATs in autoimmune diseases, NFAT-specific inhibition by VIVIT should be further investigated in suitable autoimmune animal models. We designed a drug peptide dNP2-VIVIT, which could effectively penetrate primary T cells and inhibit NFAT-dependent gene expression without affecting the calcineurin phosphatase activity. dNP2-VIVIT successfully inhibited the pathogenic function of CNS-infiltrating encephalitogenic T cells and displayed potent therapeutic effects with respect to autoimmune neuroinflammation. Importantly, whereas the CsA treatment strongly inhibited all effector T cell differentiation (Th1, Th2, Th17, and iTreg) in vitro, dNP2-VIVIT selectively inhibited the differentiation of Th1 and Th17, but not of Th2 or Treg cells. A recent study revealed that although high-dose CsA (125 mg/kg) markedly decreased EAE severity, withdrawal of CsA induced EAE relapse.54 Because Treg cells play a key role in immune system balance, CsA-mediated non-specific inhibition of both Treg cells and effector T cells may explain the rebound effect induced by a high dose of CsA. In our study, we confirmed that dNP2-VIVIT ameliorated EAE severity and incidence without affecting Treg cell functions in vivo, revealing that dNP2-VIVIT can serve as a novel agent to regulate pathogenic Th1 or Th17 cell functions to control autoimmune diseases.

Multiple sclerosis (MS) is a human autoimmune disease characterized by demyelination and axonal loss in the CNS. Studies on EAE, a model of MS, have demonstrated that myelin-specific Th1 and Th17 cells that cross the BBB are the major mediators of autoimmune encephalomyelitis. Moreover, the importance of TCR-independent innate-like Th17 cells in the pathogenicity of EAE have been recently reported. Because the NFATs has been recently reported to actively regulate lineage-specific transcription factors and signature cytokines of CD4 T helper subsets including Th1 and Th17 cells, NFATs can be a potent therapeutic target for MS. However, effective therapeutic agents that are to be used for the treatment of CNS-related diseases should be able to successfully traverse the BBB and blood-spinal cord barrier (BSCB).
Various strategies have been developed to bypass the BBB/BSCB; however, the challenge of delivering an effective therapeutic drug to the CNS is formidable. In the current study, we conjugated the VIVIT peptide with dNP2, which can efficiently penetrate the BBB and deliver cargoes to the CNS. We found that compared with 11R, dNP2 showed higher delivery efficiency with respect to entering the primary naive T cells and CNS tissues. Moreover, dNP2-VIVIT efficiently inhibited EAE progression, whereas 11R-VIVIT did not, presumably because of the difference in their delivery efficiency.

Taken together, our study collectively suggests that this is the first study to successfully regulate autoimmune neuroinflammation by targeting NFATs. Thus, we hope that dNP2-VIVIT can be further developed as a therapeutic agent against MS and other human autoimmune diseases.

MATERIALS AND METHODS

Mice

C57BL/6J mice were purchased from Orient Bio. Mice used in this study were between 6 and 9 weeks of age. All mice were maintained in the specific pathogen-free facility at Hanyang University, and all animal protocols used in this study were approved by the Animal Experimentation Ethics Committee of Hanyang University. All experiments were performed according to the guidelines of the Institutional Animal Care and Use Committees of Hanyang University.

Peptide Synthesis

dNP2-VIVIT, dNP2-VEET, and 11R-VIVIT were synthesized by Anygen. The peptides were synthesized with 97% purity; purity was confirmed by HPLC analysis.

Cell Isolation and Differentiation

Naive (CD4⁺CD25⁻CD62L⁺CD44⁻) T cells from the spleens and lymph nodes of 6- to 9-week-old mice were isolated using a Naive T Cell Isolation Kit II (Miltenyi Biotec). Purified naive CD4⁺ T cells were stimulated with plate-bound anti-CD3/CD28 (2 μg/mL; BD Biosciences). The cells were incubated in the presence of the following cytokines for 3 or 5 days: anti-IL-4 neutralizing antibody (5 μg/mL; BD Biosciences), IL-2 (50 U/mL; PeproTech), and IL-12 (2 ng/mL; Pepro-Tech) for Th1; anti-IFN-γ neutralizing antibody (5 μg/mL; BD Biosciences), IL-4 (30 ng/mL; BD Biosciences), and IL-2 (50 U/mL; Pepro-Tech) for Th2 cells; anti-IL-4/IFN-γ neutralizing antibody (5 μg/mL; BD Biosciences), TGF-β (1 ng/mL; R&D Systems), IL-6 (30 ng/mL; BD Biosciences), IL-1β (20 ng/mL; R&D Systems), and IL-23 (20 ng/mL; R&D Systems) for Th17; IL-2 (100 U/mL; PeproTech) and TGF-β (5 ng/mL; R&D Systems) for iTreg cells. Th2 cells were harvested at day 5 and were further reactivated by plate-bound anti-CD3/CD28 (2 μg/mL) for 24 h. Cells were incubated with dNP2-VEET (1 μM), dNP2-VIVIT (1 μM), and CsA (20 ng/mL; Calbiochem).
Flow Cytometry

Cell staining was performed using the following monoclonal antibodies: anti-CD4 (RM4-5; eBioscience), anti-CD25 (PC61.5; eBioscience), anti-CD44 (IM7; BioLegend), and anti-CD62L (MEL-14; BioLegend). For intracellular staining, cells were first re-stimulated with a cell stimulation cocktail (00-4975-03; eBioscience) for 4 h at 37°C, after which staining of cell surface markers was performed. After staining of the surface markers, the cells were fixed and permeabilized. Intracellular staining was performed using the following monoclonal antibodies: anti-IL-17A (eBio17B7; eBioscience), anti-IFN-γ (XMG1.2; eBioscience), anti-IL-4 (11B11; BioLegend), anti-IL-13 (eBio13A; eBioscience), and anti-Foxp3 (FJK-16s; eBioscience). Stained cells were detected by flow cytometry (FACSCanto II; BD Biosciences), and data were analyzed using FlowJo software version 10.0.7 (Tree Star).

Experimental Autoimmune Encephalomyelitis

C57BL/6j mice were immunized with 100 μg of MOG35–55 peptide in complete Freund’s adjuvant (Hooke Laboratories). At 0 and 24 h after immunization, the mice were intraperitoneally treated with 100 ng of pertussis toxin (PTX) (Hooke Laboratories). dNP2-VIVIT after immunization, the mice were intraperitoneally treated with 100 μg of pertussis toxin (PTX) (Hooke Laboratories). dNP2-VIVIT after immunization, the mice were intraperitoneally treated with 100 ng of pertussis toxin (PTX) (Hooke Laboratories). IFN-γ, IL-17A, IL-13, and Foxp3 monoclonal antibodies: anti-IL-17A (eBio17B7; eBioscience), anti-IFN-γ (XMG1.2; eBioscience), anti-IL-4 (11B11; BioLegend), anti-IL-13 (eBio13A; eBioscience), and anti-Foxp3 (FJK-16s; eBioscience). Stained cells were detected by flow cytometry (FACSCanto II; BD Biosciences), and data were analyzed using FlowJo software version 10.0.7 (Tree Star).

In Vitro Delivery Efficiency of dNP2

Naive (CD4–CD25–CD62LhighCD44low) T cells from the spleens and lymph nodes of 6- to 9-week-old mice were isolated using a Naive T Cell Isolation Kit II (Miltenyi Biotec). Purified naive CD4+ T cells were cultured in 96-well plates at 2.5 × 10^5 per well. Cells were incubated with dTomato, 11R-dTomato, and dNP2-dTomato proteins for 1 h. Following incubation, the cells were harvested and washed with PBS. Intracellular fluorescence was detected by flow cytometry (FACSCanto II; BD Biosciences), and data were analyzed using FlowJo software version 10.0.7 (Tree Star).

Imaging of Brain and Spinal Cord

C57BL/6j mice were intravenously injected with 5 mg of dTomato, dNP2-dTomato, and 11R-dTomato. Two hours after the injection, the mice were euthanized and the tissues were harvested. All harvested tissues were washed with PBS and fixed with 4% paraformaldehyde. The tissues were then frozen using O.C.T. compound (WAKO Chemical). The frozen blocks of tissues were cut into 7-μm-thick slices using cryostat (Thermo Scientific) and examined via fluorescence microscopy (Leica Microsystems).

Statistics

Data were analyzed using a two-tailed Student’s t test or two-way ANOVA using GraphPad Prism, version 6.0 (GraphPad Software). P values <0.05 were considered statistically significant.

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at https://doi.org/10.1016/j.omtm.2019.10.006.

AUTHOR CONTRIBUTIONS

J.-M.C. conceived, designed, and supervised the study. L.-K.K. performed most of the experiments. H.-G.L., L.-K.K., and J.-M.C. analyzed and discussed the data. H.-G.L. wrote the draft manuscript. J.-M.C. wrote and revised the manuscript.

CONFLICTS OF INTEREST

The authors declare no competing interests.

ACKNOWLEDGMENTS

This research was supported by the Bio & Medical Technology Development Program (NRF-2017M3A9C8027972) and by the Basic Science Research Program (NRF-2019R1A2C3006155) of the National Research Foundation (NRF) funded by the Korean Government.

REFERENCES


